Last reviewed · How we verify
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — Portfolio Competitive Intelligence Brief
15 marketed
0 filed
4 Phase 3
1 Phase 2
2 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Placebo (for flucloxacillin) | Placebo (for flucloxacillin) | marketed | ||||
| Cephalozin | Cephalozin | marketed | Other | |||
| Fixed low dose tinzaparin | Fixed low dose tinzaparin | marketed | Low-molecular-weight heparin (LMWH) | Antithrombin III (indirect target); Coagulation factors Xa and IIa | Cardiovascular / Thromboembolism | |
| ferric(III)carboxymaltose | ferric(III)carboxymaltose | marketed | Iron replacement agent | Iron metabolism / transferrin-mediated iron transport | Hematology | |
| PRECISION dosing Infliximab | PRECISION dosing Infliximab | marketed | TNF-alpha inhibitor monoclonal antibody | TNF-alpha (Tumor Necrosis Factor-alpha) | Immunology | |
| Endotoxin | Endotoxin | marketed | Non-Standardized Food Allergenic Extract [EPC] | Other | ||
| Low dose nadroparin | Low dose nadroparin | marketed | Low-molecular-weight heparin (LMWH) | Factor Xa, Thrombin (Factor IIa) | Cardiovascular | |
| Intermediate dose dalteparin | Intermediate dose dalteparin | marketed | Low-molecular-weight heparin (LMWH) | Antithrombin III (indirect); Factor Xa and Thrombin (downstream targets) | Cardiovascular | |
| Intermediate dose nadroparin | Intermediate dose nadroparin | marketed | Low-molecular-weight heparin (LMWH) | Factor Xa, Thrombin (via antithrombin III enhancement) | Cardiovascular | |
| Rapidly Cycled HAART | Rapidly Cycled HAART | marketed | Antiretroviral therapy regimen (combination therapy) | Infectious Disease / Virology | ||
| Fluticasone proprionate 0.05% cream | Fluticasone proprionate 0.05% cream | marketed | Topical corticosteroid | Glucocorticoid receptor | Dermatology | |
| Intermediate dose enoxaparin | Intermediate dose enoxaparin | marketed | Low-molecular-weight heparin (LMWH) | Coagulation factors Xa and IIa (via antithrombin III) | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 5
- Other · 3
- Immunology · 3
- Critical Care / Intensive Care Medicine · 1
- Dermatology · 1
- Hematology · 1
- Cardiovascular / Hematology · 1
- Infectious Disease / Virology · 1
- Oncology · 1
- Oncology; Immunology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Medical University of Vienna · 2 shared drug classes
- Biocad · 2 shared drug classes
- GlaxoSmithKline · 2 shared drug classes
- LEO Pharma · 2 shared drug classes
- University of Utah · 2 shared drug classes
- American Regent, Inc. · 1 shared drug class
- All India Institute of Medical Sciences, Bhubaneswar · 1 shared drug class
- Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA):
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) pipeline updates — RSS
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) pipeline updates — Atom
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/academisch-medisch-centrum-universiteit-van-amsterdam-amc-uva. Accessed 2026-05-17.